Search

everythinglearnresearchcommunity

for

Search:↓

Corticosteroid pulse therapy is more effective for severe alopecia areata than combination therapy.

Oral cyclosporine is more effective and safer than betamethasone for treating alopecia areata.

A girl with lupus had unusually long and thick eyelashes, a rare symptom of her condition.

Some drugs can cause rare but potentially deadly skin reactions, and early treatment and avoiding the drug again are key.

A 5-year-old boy's skin condition improved with systemic valganciclovir after a cardiac transplant and immunosuppressive therapy.

A young woman with lupus was treated with hydroxychloroquine and prednisone.

Topical treatments helped a child with Down syndrome and severe hair loss regrow most of his hair.

The document says a skin condition called alopecia areata causes hair loss and stress, and is treated with strong skin creams, injections, or other therapies, but treatment success varies.

Guidelines suggest various treatments for alopecia areata, but leaving it untreated is also an option as 80% cases may recover on their own.

Alopecia Areata is an unpredictable autoimmune hair loss condition with limited and variable treatment effectiveness.

Alopecia Areata is a hair loss condition affecting all genders, often linked to other diseases, with treatments available but varying success rates.

Some drugs can cause hair loss, change hair color and shape, or increase hair growth, and treatment may involve stopping the drug or using specific hair growth treatments.

Some treatments can help with hair regrowth in alopecia areata, but results vary and long-term use is often needed without changing the disease's outcome.

Hair loss is common in lupus patients and can be permanent or reversible, depending on the type, with various treatments available.

Cyclosporine showed some improvement in alopecia areata but results were not statistically significant.

Azathioprine's effectiveness and safety require careful monitoring and more research, especially regarding its use with corticosteroids and the role of TPMT status in patients.

New treatments for a chronic skin condition show promise, but individualized plans are crucial due to varying responses.

The document says that treating the root cause of hair follicle damage is crucial to prevent permanent hair loss, and treatment options vary.

A patient with complete hair loss regrew all her hair using tofacitinib.

A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.

A patient with Rhupus was diagnosed with Rowell syndrome and treated with various medications.

Intralesional corticosteroids are the best for limited alopecia areata, oral steroids are less effective, and PRP is safe and promising, especially for children and severe cases.

Early diagnosis and aggressive treatment are crucial for Cicatricial Alopecia, and treatment effectiveness varies among patients.

Only minoxidil and finasteride are FDA-approved for hair loss, with other treatments available but less effective or with side effects.

JAK inhibitors are effective for hair regrowth in severe alopecia areata.

Cyclosporine effectively treated a woman's stubborn skin condition.

Current treatments for folliculitis decalvans include antibiotics, isotretinoin, and potential new therapies like botulinum toxin A and PRP.

Acne is linked to inflammation and insulin resistance, and is associated with various syndromes that require different treatments.

The document concludes that early recognition and treatment of primary cicatricial alopecia is crucial to prevent permanent hair loss.

Alopecia areata treatment should be personalized, using topical or systemic therapies based on severity, with promising options like JAK inhibitors needing more research.